REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot209710.32687/1561-5936-2026-30-3-284-288Original ArticlePublic-private partnership as a tool for attracting investments in domestic pharmaceutical productionRomashchenkoVictoria A.romashchenko-va@rudn.ruGubachevNikolay N.gubachev-nn@rguk.ruPeoples' Friendship University of Russia named after Patrice Lumumba, Moscow, RussiaA. N. Kosygin Russian State University (Technology. Design. Art), Moscow, Russia2809202630328428829092026Copyright © 2026,2026The article explores the role of public-private partnership (PPP) as a mechanism for attracting long-term investments in the domestic pharmaceutical sector in the context of sanctions pressure and the need to ensure the countrys drug security. Based on the analysis of the regulatory framework, the systematization of foreign and Russian experience in implementing PPP projects in the pharmaceutical industry, and the methods of comparative analysis, the article identifies institutional barriers that hinder the widespread use of this mechanism in domestic practice. The author proposes a typology of PPP models applicable to pharmaceutical production and identifies key conditions under which a partnership between the government and private capital can achieve maximum synergy. The paper substantiates the need to develop an industry-specific standard for PPP agreements in the pharmaceutical industry and formulates proposals for improving the mechanisms of state support for the investment activity of private participants. The results contribute to the development of PPP theory in relation to high-tech, knowledge-intensive industries.public-private partnershippharmaceutical industryinvestmentdrug safetyimport substitutionconcession agreementspecial investment contractpharmaceutical sovereigntyгосударственно-частное партнёрствофармацевтическая промышленностьинвестициилекарственная безопасностьимпортозамещениеконцессионное соглашениеспециальный инвестиционный контрактфармацевтический суверенитет1.Yescombe E. R. Public-private partnerships: principles of policy and finance. Oxford; 2007.2.Behn R. D. Performance Stat potential: a leadership strategy for producing results. Washington, D.C.; 2014.3.Hodge G. A., Greve C. The challenge of public-private partnerships: learning from international experience. Cheltenham; 2005.4.Varnavsky V. Public-private partnership: some issues of theory and practice. World Economy and International Relations. 2011;(9):41—50. (In Russ.)5.Chaudhuri S. Technology transfer and pharmaceutical industry in India. Econ. Polit. Wkly. 2005;40(39):4295—4304.6.Pasechnik I. A. Public-private partnership as a tool for achieving the goals of sustainable development of the Russian Federation. World Science. 2025;(1(94)):89—95. EDN: PLOEPE. (In Russ.)7.Yagovkina N. V., Gabrielyan A. R., Demuria L. E. et al. The market of public-private partnership projects in healthcare in the Russian Federation: structure and trends. Remedium. 2025;29(2):143—150. doi: 10.32687/1561-5936-2025-29-2-143-150 (In Russ.)8.Kulikov V. A. Features of the development of public-private partnership in the Russian Federation. Economic Vector. 2023;(2(33)):73—76. doi: 10.36807/2411-7269-2023-2-33-72-76 (In Russ.)9.Petrov Yu. A., Tikhomirova M. V. Investment climate in the pharmaceutical industry of Russia: assessment of regulatory risks. Russian Management Journal. 2021;19(2):105—124. (In Russ.)